Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for NovaBay Pharmaceuticals (NBY) over the last 4 years, with Q3 2025 value amounting to $87000.0.

  • NovaBay Pharmaceuticals' Asset Writedowns and Impairment changed N/A to $87000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $676000.0, marking a year-over-year change of. This contributed to the annual value of $2.6 million for FY2023, which is 6151.11% down from last year.
  • According to the latest figures from Q3 2025, NovaBay Pharmaceuticals' Asset Writedowns and Impairment is $87000.0.
  • In the past 5 years, NovaBay Pharmaceuticals' Asset Writedowns and Impairment registered a high of $589000.0 during Q1 2025, and its lowest value of $87000.0 during Q3 2025.